SMO and cancer: In the subgroup analysis, the survival advantage of patients with SMO mutations receiving ICI treatment over the SMO_WT patients was prominent and consistent across each subgroup, including age, gender, cancer type, treatment type, and TMB status (all pinteraction > 0.05) (Figure 2D).